Welcome to our dedicated page for Dermata Therapeutics SEC filings (Ticker: DRMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Dermata Therapeutics, Inc. filings document a dermatology-focused operating company with common stock and publicly traded warrants, a direct-to-consumer skincare strategy and ongoing capital-structure activity. Recent Form 8-K reports cover annual and quarterly operating results, prospectus supplements for at-the-market common stock sales, private financing-related disclosure, and material agreements tied to the company's shift away from pharmaceutical development.
Dermata's proxy and governance filings address shareholder voting matters, board composition and corporate governance. Other current reports document changes in the independent registered public accounting firm, director resignation disclosures, going-concern context in auditor reports, and material-agreement disclosure involving the Villani license and the XYNGARI investigational new drug application.
Dermata Therapeutics reported new clinical data from its Phase 3 STAR-1 trial of XYNGARI™ (DMT310) for acne, presented in an abstract at the 2025 European Academy of Dermatology and Venereology Congress. In an intent-to-treat analysis, XYNGARI showed statistically significant improvements versus placebo in multiple measures, including Investigator Global Assessment (IGA) treatment success, inflammatory lesion counts, and non-inflammatory lesion counts at weeks 4, 8, and 12.
For IGA treatment success defined as a 2-point reduction and a score of 0 or 1, XYNGARI achieved 29.4% of patients at week 12 compared with 15.2% on placebo. XYNGARI also had greater mean and percent reductions from baseline in both inflammatory and non-inflammatory lesion counts across all time points, supporting a consistent efficacy benefit over placebo in this Phase 3 acne study.